Oesophageal cancer: new developments in systemic therapy.
about
Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junctionChemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junctionNedaplatin: a cisplatin derivative in cancer chemotherapyEsophageal adenocarcinoma arising from Barrett's dysplasia: a case report of double occurrence and prolonged survival after chemotherapyA phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinomaGALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma.ATF3 functions as a novel tumor suppressor with prognostic significance in esophageal squamous cell carcinoma.Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk.Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse modelsFirst-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II studyNimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinomaPIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.Analysis of NF-kappaB signaling pathways by proteomic approaches.Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial.Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.Expression of decorin in esophageal cancer in relation to the expression of three isoforms of transforming growth factor-beta (TGF-beta1, -beta2, and -beta3) and matrix metalloproteinase-2 activity.
P2860
Q24235532-A8AE8218-C912-4671-8455-EA21E15A423FQ24244263-11A7B234-E61F-49CE-BFCA-0D2B8BB6BEB4Q24623561-6CC40C95-ED70-4AC4-8786-8358614EA04AQ28200513-2BF0FA91-C222-474C-B5EE-CC13499ADD22Q33405628-EE065796-7C65-4123-BC58-A506AC679AC8Q33410922-16175C41-365F-4AE1-BFF0-987503C0B5FEQ33710048-C38E921D-70E4-4F80-AB91-90086C1ADB55Q34483678-3E694635-86E8-4E68-9D43-EF0516911101Q35019371-3B836069-B49C-4D0A-AAA7-C208F5306FD6Q36055127-27C36922-F0C3-4B78-9F65-492AE5A8F31CQ36361515-D30D556A-FC03-49CA-B8BE-500E9E42D264Q36610452-43957FD9-A111-45EA-8F63-05A24F24FFBCQ36801223-3B243EEE-8514-476F-B228-3AA1F52D18DCQ36940910-B45835BF-DB57-47EB-9E21-4F902A2BCEB1Q37327580-CE9C2457-2AC9-4274-A93C-23A180A96EB2Q37727184-A8D97C61-1092-4607-B65B-B5952DD25A15Q39363981-D8974F46-2563-40FD-937F-4FEFEF680286Q51512708-B8F733E1-6B7B-494E-9BFA-EFB25E2B4C29Q51824976-670053E7-50EA-4C79-BCF6-9A7C69A25143
P2860
Oesophageal cancer: new developments in systemic therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Oesophageal cancer: new developments in systemic therapy.
@ast
Oesophageal cancer: new developments in systemic therapy.
@en
type
label
Oesophageal cancer: new developments in systemic therapy.
@ast
Oesophageal cancer: new developments in systemic therapy.
@en
prefLabel
Oesophageal cancer: new developments in systemic therapy.
@ast
Oesophageal cancer: new developments in systemic therapy.
@en
P1476
Oesophageal cancer: new developments in systemic therapy.
@en
P2093
David H Ilson
P304
P356
10.1016/S0305-7372(03)00104-X
P577
2003-12-01T00:00:00Z